sophoraflavone G | 1049662-29-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: sophoraflavone G
• 英文别名: sophoraflavanone G；norkurarinone；(2S)-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-8-(5-methyl-2-prop-1-en-2-ylhex-4-enyl)-2,3-dihydrochromen-4-one
• CAS: 1049662-29-4
• 化学式: C₂₅H₂₈O₆
• 分子量: 424.494
• InChiKey: XRYVAQQLDYTHCL-GMTBNIFVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  107
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  乙酸酐 、 sophoraflavone G 在 吡啶 作用下， 生成 Acetic acid (S)-7-acetoxy-2-(2,4-diacetoxy-phenyl)-8-(2-isopropenyl-5-methyl-hex-4-enyl)-4-oxo-chroman-5-yl ester
  参考文献：
  名称：

  摘要：

  DOI：

  10.1023/a:1010450709980
• 作为产物：
  描述：

  dimethylallyl diphosphate 、 草大戟素; 2',4',5,7-四羟基黄烷酮 在 naringenin 8-dimethylallyltransferase 、 magnesium chloride 作用下， 以 乙醇 、 水 为溶剂， 生成 sophoraflavone G 、 8-dimethylallylsteppogenin 、 cudraflavanone B
  参考文献：
  名称：

  Flavanone 8-dimethylallyltransferase in Sophora flavescens cell suspension cultures

  摘要：

  Dimethylallyl diphosphate: naringenin 8-dimethylallyltransferase (EC 2.5.1) was characterized. The enzyme was enantiospecific for (-)-(2S)-naringenin and utilized 3,3-dimethylallyl diphosphate as sole prenyl donor. It required Mg2+ (optimum concentration, 10 mM), and has an optimum pH of 9-10. The apparent K-m values for 3,3-dimethylallyl diphosphate and naringenin were 120 and 36 mu M, respectively. The microsomal fraction prenylated several other flavanones at the C-8 position less effectively as compared with naringenin. Interestingly, when 2'-hydroxynaringenin was used as a prenyl acceptor, the 8-lavandulyl (sophoraflavanone G) and the 6-dimethylallyl derivatives were formed, together with the 8-dimethylallyl derivative, leachianone G. These results suggest that the 2'-hydroxy group of naringenin plays an important role for the formation of a lavandulyl group. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0031-9422(00)00198-9

文献信息

• T-TYPE CALCIUM CHANNEL INHIBITOR
  申请人：KINKI UNIVERSITY

  公开号：US20160096815A1

  公开（公告）日：2016-04-07

  The present invention provides a T-type calcium channel inhibitor which is a compound represented by formula (1), a pharmaceutically acceptable salt of this compound or a solvate of this compound. The present invention also provides: this T-type calcium channel inhibitor; a pharmaceutical product containing this T-type calcium channel inhibitor; and a therapeutic agent or prophylactic agent for diseases, the effective action of which is a T-type calcium channel inhibitory action. (In formula (1), each of R 1 and R 2 independently represents H, —OH or —OR 11 , wherein R 11 represents a C 1-3 alkyl group; each of R 3 and R 4 independently represents H, —OH or —OR 12 , wherein R 12 represents a C 1-3 alkyl group; and each of R 5 and R 6 independently represents H, a halogen atom, a C 1-10 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a phenyl group (which may be substituted by a C 1-6 alkoxy group or a halogen atom), a —C 1-3 alkyl-phenyl group (which may be substituted by a C 1-6 alkyloxy group or a halogen atom) or a C 10-50 prenyl group.)

  本发明提供了一种T型钙通道抑制剂，该化合物由式（1）表示，其药学上可接受的盐或该化合物的溶剂。本发明还提供：该T型钙通道抑制剂；含有该T型钙通道抑制剂的药物产品；以及治疗或预防疾病的治疗剂或预防剂，其有效作用是T型钙通道抑制作用。（在式（1）中，每个R1和R2独立地表示H，—OH或—OR11，其中R11表示C1-3烷基；每个R3和R4独立地表示H，—OH或—OR12，其中R12表示C1-3烷基；每个R5和R6独立地表示H，卤素原子，C1-10烷基，C2-6烯基，C2-6炔基，苯基（可能被C1-6烷氧基或卤素原子取代），—C1-3烷基苯基（可能被C1-6烷氧基或卤素原子取代）或C10-50戊二烯基。）
• T-type calcium channel inhibitor
  申请人：KINKI UNIVERSITY

  公开号：US10633358B2

  公开（公告）日：2020-04-28

  The present invention provides a T-type calcium channel inhibitor which is a compound represented by formula (1), a pharmaceutically acceptable salt of this compound or a solvate of this compound. The present invention also provides: this T-type calcium channel inhibitor; a pharmaceutical product containing this T-type calcium channel inhibitor; and a therapeutic agent or prophylactic agent for diseases, the effective action of which is a T-type calcium channel inhibitory action. (In formula (1), each of R1 and R2 independently represents H, —OH or —OR11 wherein R11 represents a C1-3 alkyl group; each of R3 and R4 independently represents H, —OH or —OR12, wherein R12 represents a C1-3 alkyl group; and each of R5 and R6 independently represents H, a halogen atom, a C1-10 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, a phenyl group (which may be substituted by a C1-6 alkoxy group or a halogen atom), a —C1-3 alkyl-phenyl group (which may be substituted by a C1-6 alkyloxy group or a halogen atom) or a C10-50 prenyl group.)

  本发明提供了一种 T 型钙通道抑制剂，它是由式（1）代表的化合物、该化合物的药学上可接受的盐或该化合物的溶液。本发明还提供：这种 T 型钙通道抑制剂；含有这种 T 型钙通道抑制剂的药品；以及一种治疗剂或疾病预防剂，其有效作用为 T 型钙通道抑制作用。式（1）中，R1 和 R2 各自独立地代表 H、-OH 或-OR11，其中 R11 代表 C1-3 烷基；R3 和 R4 各自独立地代表 H、-OH 或-OR12，其中 R12 代表 C1-3 烷基；R5和R6各自独立地代表H、卤素原子、C1-10烷基、C2-6烯基、C2-6炔基、苯基（可被C1-6烷氧基或卤素原子取代）、-C1-3烷基苯基（可被C1-6烷氧基或卤素原子取代）或C10-50链烯基。)
• Chemosensory receptor ligand-based therapies
  申请人：Anji Pharma (US) LLC

  公开号：US10610500B2

  公开（公告）日：2020-04-07

  Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.

  本文提供了通过施用包含化感受体配体（如苦味受体配体）的组合物来治疗与化感受体相关的病症（包括糖尿病、肥胖症和其他代谢性疾病、失调或病症）的方法。本文还提供了化学感觉受体配体组合物，包括苦味受体配体组合物，及其用于本发明方法的制备方法。本文还提供了包含二甲双胍及其盐类的组合物和使用方法。
• CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES
  申请人：Anji Pharma (US) LLC

  公开号：EP2661266B1

  公开（公告）日：2020-09-16
• EP3000465B1
  申请人：——

  公开号：EP3000465B1

  公开（公告）日：2021-03-31

表征谱图